Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Northrop Grumman Corporation (NOC) vs New York Times Co (NYT) Price & Performance

Northrop Grumman CorporationTrade
New York Times CoTrade

Price performance (Past 24H)

Key statistics

Northrop Grumman Corporation vs New York Times Co — how do they compare? Northrop Grumman Corporation trades at $479.5 (market cap $68.83B), while New York Times Co trades at $65.42 (market cap $10.74B). The key difference: Northrop Grumman Corporation is far larger — about 6.4× New York Times Co's market cap, and Northrop Grumman Corporation pays the higher dividend (2.04%). Which is the better fit depends on your goals — on Pluang, investors hold Northrop Grumman Corporation for 81 Days and New York Times Co for 81 Days on average.

NOCNYT
Market Cap
$68.83B$10.74B
Volume
1,081,9892,096,352
Sector
IndustrialsMedia
52-Week High
$768.02$85.86
52-Week Low
$473.46$54.66
Typical Hold Time
81 Days81 Days
Enterprise Value
$82.81B$10.14B
Dividend Yield
2.04%1.38%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Northrop Grumman Corporation

Northrop Grumman (NOC) trades at $480.85, up 1.56% with recent earnings beats but faces technical bearish signals. The company maintains strong fundamentals with $41.95B revenue, 10.48% net margin, and attractive valuation at 15.4 P/E. Recent news highlights both contract wins and competitive losses, including Boeing's $20B Navy fighter award.

Outlook remains positive with analyst consensus at $600.62 target (25% upside) and 54% buy ratings. Key risks include defense contract volatility and competitive pressures, while strong backlog ($104.7B) and dividend growth support long-term value. The stock offers defensive exposure to elevated defense spending cycles.

New York Times Co

The New York Times Company (NYSE: NYT) trades at $65.64, up 1.14% today, with a bullish technical signal and strong fundamentals. Revenue grew from $2.3B in 2022 to $2.8B in 2025, with net income margin expanding to 12.17%. Recent earnings beats and a declared $0.23 dividend highlight operational strength, though a shareholder lawsuit presents headline risk.

Outlook is positive given consistent earnings outperformance and analyst consensus target of $84.00, implying 28% upside. Key risks include the pending lawsuit's impact on reputation and competitive pressures in digital media. Cash flow generation remains robust, supporting dividend sustainability and growth initiatives.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NOC
100% Buy0% Sell
Avg holding period · 81 Days
NYT
0% Buy100% Sell
Avg holding period · 81 Days

Top news

Latest headlines on both assets

About Northrop Grumman Corporation

Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.

Read more on NOC →

About New York Times Co

New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.

Read more on NYT →